Acute Coronary Syndrome: What Is Safer, Antiaggregant Monotherapy or De-Escalation?

For several years it has been shown that 12-month dual antiplatelet therapy (DAPT) is mandatory for patients undergoing left main PCI for acute coronary syndrome (ACS). However, though this strategy does reduce thrombotic events and mortality, it also causes undesirable bleeding events followed by hospitalization and antiaggregation interruption for a period of time. 

Síndromes coronarios agudos: ¿Qué es más seguro: monoterapia con antiagregante o De-Escalation?

A feasible strategy could be to interrupt one of the antiaggregants (be it aspirin -ASA- or P2Y12 inhibitor). The alternative could be to switch (De-Escalation) to a P2Y12 inhibitor of lower antiaggregation power (for example from prasugrel or ticagrelor to clopidogrel) or to reduce dosage.

This question remains unanswered.

This meta-analysis included 29 studies with 50602 patients, and it compared short duration antiaggregation (SHORT DAPT) vs. de-escalation.

Mean age was 63, there was an important number of women and a percentage of diabetics that ranged between 22% and 26%. There were no differences in all-cause mortality. 

De-escalation reduced the risk of net adverse cardiovascular events (NACE) (RR: 0.87; 95% CI: 0.70-0.94) but increased the risk of major bleeding (RR: 1.54; 95% CI: 1.07-2.21).

Read also: IVUS in Acute Coronary Syndrome: A New Requirement?

De-Escalation showed >95% probability to prevent NACE, MI, stroke, stent-thrombosis, and minor bleeding. However, it showed a very high rate of major bleeding. 

On the other hand, the SHORT DAPT approach showed better performance (>95%) in the prevention of major bleeding.

Conclusion

In patients with acute coronary syndrome undergoing PCI there were no differences in all-cause mortality between SHORT DAPT and De-Escalation. De-Escalation reduced NACE risk, while SHORT DAPT reduced the risk of major bleeding. 

These data characterize 2 contemporary strategies to personalize the use of DAPT according to treatment goals and risk profile.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the SOLACI.org Editorial Board. 

Original Title: Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes.

Reference: Claudio Laudani, et al. J Am Coll Cardiol Intv 2022;15:268–277.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

ACC 2026 | DKCRUSH VIII: IVUS or angiography to guide PCI in complex coronary bifurcations

Intracoronary imaging guidance has become an established recommended strategy in complex coronary lesions. In the specific setting of complex bifurcations, uncertainty remained regarding the...

ACC 2026 | OPTIMAL: IVUS Guidance in PCI of the Unprotected Left Main Coronary Artery

Percutaneous coronary intervention (PCI) is considered an equivalent alternative to coronary artery bypass surgery in patients with left main coronary artery (LMCA) stenosis and...

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...